NCT04039763Recruiting
RT-CGM in Young Adults at Risk of DKA
Assessment of the Impact of Real-time Continuous Glucose Monitoring on Glycaemic Control in High-risk Adolescents and Young Adults With Insulin-treated Diabetes
Source: ClinicalTrials.gov · Last updated 24 Jun 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Pilot study to evaluate the effect of real time continuous glucose monitoring (RT-CGM) on young-adults with insulin-treated diabetes, who are defined as high risk due to suboptimal HbA1c (blood glucose control) or a history of hospital admissions for high blood glucoses. Hypothesis: RT-CGM provided to young adults with suboptimal blood glucose control, has a beneficial impact on HbA1c and hospital admissions for high blood glucoses. We will use data from this pilot work to inform a larger powered study to address this knowledge gap.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 30 Jul 2019
- Start date
- 3 Sept 2020
- Primary completion date
- 30 Jun 2022
- Lead sponsor
- Imperial College London
- Diseases
- Type 1 diabetes
- NCT number
- NCT04039763
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 3 Sept 2020 to the primary completion date, 30 Jun 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have active malignancy or under investigation for malignancy
- Severe visual impairment
Lab values
- Chronic kidney disease eGFR \<30ml/min
Other
- Pregnant or planning pregnancy
- Breastfeeding
- Reduced manual dexterity
- Unable to participate due to other factors, as assessed by the Chief Investigator
Who the study is looking for
- Adolescents and young adults aged 18-25 years
- Insulin-treated diabetes \>12 months (on multiple daily injections or insulin pump therapy)
- HbA1c \> 75 mmol/mol (9%) or 1 or more DKA admissions in the last 12 months or 1 or more admissions with uncontrolled blood glucose levels in the last 12 months.
- Naïve to RT-CGM - except for short periods for use for diagnosis or monitoring purposes.
- Use of prior flash glucose monitoring is permittable
Age in the registry: 18 years to 25 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Imperial College Clinical Research Facility Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.